IPF患者气道上皮细胞的转录组特征及治疗启示
该研究对初诊未治疗的特发性肺纤维化(IPF)患者气道黏膜进行气液界面培养的单细胞RNA测序,分析了129 986个转录组,识别出启动型成纤维细胞、失调的基底细胞和促炎气道上皮细胞。体外实验显示支气管上皮细胞可刺激成纤维细胞增殖和活化,三种药物均能减弱IPF特征,其中saracatinib对成纤维细胞活化和上皮增殖的抑制最有效。
要点
- 初诊未治疗IPF患者气道黏膜存在启动型成纤维细胞和失调基底细胞等早期细胞表型。
- 支气管上皮细胞可刺激成纤维细胞增殖和活化,成纤维细胞仍对TGF-β敏感。
- saracatinib在体外最有效抑制成纤维细胞活化和上皮增殖,优于尼达尼布和吡非尼酮。
核心结论
- 本研究定义了IPF早期诊断阶段气道黏膜的上皮-间质程序,并在单细胞分辨率下展示了不同药物反应。
- 通过将气道来源表型与抗纤维化疗效关联,研究结果提示saracatinib具有治疗潜力。
研究设计与样本
- 对初诊未治疗IPF患者气道黏膜进行气液界面培养的单细胞RNA测序,共分析129 986个转录组。
- 体外评估细胞对尼达尼布、吡非尼酮和Src激酶抑制剂saracatinib的转录和功能反应。
主要发现
- 识别出启动型成纤维细胞(PDGFRA+、SPP1+)、失调基底细胞(TP63+、KRT5+、FN1+)和促炎气道上皮细胞(SAA、CXCL、CCL)。
- 与 explant 来源的IPF图谱整合分析显示不同基底和成纤维细胞表型跨越组织区域和疾病阶段。
- 体外支气管上皮细胞刺激成纤维细胞增殖和活化,成纤维细胞保持对TGF-β的敏感性。
- 三种药物均减弱许多IPF特征,saracatinib最有效抑制成纤维细胞活化和上皮增殖。
临床怎么用
- 提示气道黏膜单细胞转录组特征可用于早期IPF机制解析和药物反应评估。
- saracatinib在体外显示出优于尼达尼布和吡非尼酮抑制成纤维细胞活化和上皮增殖的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited treatment options. Most single-cell studies rely on end-stage explant lungs, leaving early disease mechanisms poorly understood. Profiling earlier stages may reveal distinct cellular phenotypes that could be pharmacologically targeted. Recent evidence also implicates airway epithelial cells in IPF disease development and progression. METHODS: To investigate early-stage IPF mechanisms, we profiled the airway mucosa of newly diagnosed, treatment-naïve patients using single-cell RNA-sequencing of air-liquid interface cultures. We further assessed the transcriptional and functional responses of these cells to antifibrotic drugs (nintedanib and pirfenidone) and a Src kinase inhibitor (saracatinib). RESULTS: Profiling of 129 986 transcriptomes identified primed fibroblasts (PDGFRA +, SPP1 +), dysregulated basal cells (TP63+ , KRT5+ , FN1+ ), and proinflammatory airway epithelial cells (SAA, CXCL, CCL). Integrative analyses with explant-derived IPF atlases revealed different basal and fibroblast phenotypes spanning tissue regions and disease stages. In vitro, bronchial epithelial cells stimulated fibroblast proliferation and activation, and fibroblasts remained sensitive to TGF-β. While all three drugs attenuated many IPF signatures, saracatinib most effectively suppressed fibroblast activation and epithelial proliferation. CONCLUSIONS: This study defines epithelial-mesenchymal programmes of the airway mucosa at an early, diagnostic stage of IPF and demonstrates distinct drug responses at single-cell resolution. By linking airway-derived phenotypes to antifibrotic efficacy, our findings highlight the therapeutic potential of saracatinib and may inform future treatment strategies.
引用
- Chua RL, Veith C, Schneider MA, et al. Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications. Thorax. 2026. PMID: 41713905. doi:10.1136/thorax-2025-223325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。